177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study
European Journal of Cancer · 2025-10 · 229 · 115789
DOI: 10.1016/j.ejca.2025.115789 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2025-10. Verfasst von Philipp Mandel und 37 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany; Martini-Klinik Prostate Cancer Center, Universit…. Hauptthemen laut MEDLINE: Dipeptides, Heterocyclic Compounds, 1-Ring, Lutetium, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation Medicine.
Abstract (Originalsprache)
BACKGROUND: Radioligand therapy with [177Lu]Lutetium-177-PSMA-617 (177Lu-PSMA) was recently introduced in clinical practice in the US, Latin America and in most European countries for progressive, metastatic castration-resistant prostate cancer (mCRPC). However, multicenter real-world data on cancer-control outcomes are scant. METHODS: Real-word data from the ARON-3 collaboration in progressive mCRPC patients treated with 177Lu-PSMA vs. cabazitaxel were collected. A retrospective analysis was performed, including overall survival (OS), progression free survival (PFS), time to treatment failure (TTF) and PSA50/90 rates. RESULTS: Data from 285 (50.1 %) patients receiving 177Lu-PSMA vs. 283 (49.9 %) cabazitaxel after one or two lines of ARPI and Docetaxel were analyzed. PSA50 and PSA90 rates were higher, and TTF and OS were significantly longer in 177Lu-PSMA patients, even after multivariable adjustment (p ≤ 0.01). This effect held true for most subgroups such as age < 70 and ≥ 70 years, ECOG 0-1, distant lymph nodes and one vs. two lines of prior ARPI. Incidence of grade 3-4 adverse events were comparable between both treatments (37 % vs. 43 % for 177Lu-PSMA vs. cabazitaxel cohort p = 0.5) but differed according to the type of adverse events. Sensitivity analyses with cross-over adjustment showed similar effects. CONCLUSIONS: Analyzing the currently largest real-world cohort comparing 177Lu-PSMA vs. cabazitaxel, we provided robust information of 177Lu-PSMA being at least equally effective or possibly even superior to cabazitaxel regarding cancer-control outcomes with reasonable side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
- Goethe University Frankfurt, University Hospital, Department of Nuclear Medicine, Clinic for Radiology and Nuclear Medicine, Frankfurt am Main, Germany.
- Nuclear Medicine Unit, Macerata Hospital, AST, Macerata 62100, Italy.
- Medical Oncology, Ankara University Medical Faculty, Ankara, Turkey.
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
- Goethe University Frankfurt, Frankfurt am Main, Germany.
Förderung
- Foundation Medicine
Zitieren
APA
Mandel, P., Groener, D., Follacchio, G., Ürün, Y., Bourlon, M. T., Sabet, A., Grünwald, F., Tural, D., Büttner, T., Kopp, R. M., Taha, T., Chun, F. K., Facchini, G., Myint, Z. W., Seront, E., Conteduca, V., Quiroga, M. N. G., Aurilio, G., Palacios, G. A., …, & Santoni, M. (2025). 177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study. European Journal of Cancer, 229, 115789. https://doi.org/10.1016/j.ejca.2025.115789
Vancouver
Mandel P, Groener D, Follacchio G, Ürün Y, Bourlon MT, Sabet A, et al. 177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study. European Journal of Cancer. 2025;229:115789. doi:10.1016/j.ejca.2025.115789
BibTeX
@article{Mandel2025,
author = {Mandel, Philipp and Groener, Daniel and Follacchio, Giulia and Ürün, Yüksel and Bourlon, Maria T and Sabet, Amir and Grünwald, Frank and Tural, Deniz and Büttner, Thomas and Kopp, Ray Manneh and Taha, Tarek and Chun, Felix Kh and Facchini, Gaetano and Myint, Zin W and Seront, Emmanuel and Conteduca, Vincenza and Quiroga, María Natalia Gandur and Aurilio, Gaetano and Palacios, Georgia Anguera and Bögemann, Martin and Roviello, Giandomenico and Matrana, Marc R and Sammarco, Enrico and Laguado, Martin Ignacio Zapata and Galli, Luca and Ansari, Jawaher and Danielli, Linda and Molina-Cerrillo, Javier and Rescigno, Pasquale and Yazgan, Sati Coskun and Bastos, Diogo Assed and Jazieh, Abdul Rahman and Monteiro, Fernando Sabino Marques and Soares, Andrey and Massari, Francesco and Wenzel, Mike and Capoccetti, Francesca and Santoni, Matteo},
title = {177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study},
journal = {European Journal of Cancer},
year = {2025},
volume = {229},
pages = {115789},
doi = {10.1016/j.ejca.2025.115789}
}
EUVIMED